News
Gene test predicts metastasis of sentinel node-negative melanomas
Major finding: Metastasis-free survival was 31% and overall survival was 49% at 5 years in the 64 patients who had negative sentinel node lymph...
News
Blood test predicts Merkel cell carcinoma metastases
Major finding: Two cases of surgically operable, metastatic Merkel cell tumors, one metastatic to the kidney and the other to the pancreas, were...
News
Adjuvant ibandronate adds no benefit in early stage, node-positive breast cancer
Major finding: In patients randomly assigned to 2 years of ibandronate or observation, there was no difference in disease-free survival (HR, 0.945...
News
Long-term amenorrhea risk no higher for premenopausal breast cancer patients with BRCA mutations
Major finding: The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed at or before age 30 years, 33% for women...
News
Lymph node status predicted 10-year mortality in BRCA1 mutation carriers with small, stage I-III breast cancers
Major finding: Based on BRCA1 status alone, the 10-year survival rate for mutation carriers was 80.9% (95% CI, 75.4%-86.4%); for noncarriers, it...
News
Prolaris test eyed as predictor of prostate cancer outcomes
Major finding: In conservatively managed prostate cancer patients, the cell cycle progression score in tissue samples was the dominant variable...
News
Gene mutations found in 22% of African American breast cancer patients
Major finding: Of 56 African American women with gene mutations, 26 were positive for BRCA1, 20 were positive for BRCA2, and 10 were positive for...
News
Selumetinib is first therapy to shrink uveal melanomas
Major finding: Tumors regressed in 11% (RECIST response, 0%) of 46 evaluable patients in the temozolomide arm and in 50% (RECIST response, 15%) of...
News
Oral idelalisib elicits response in half of refractory CLL patients
Major finding: Single agent idelalisib elicited 2 complete responses and 28 partial responses in 54 heavily pretreated patients with chronic...
News
Dual immunotherapy scores rapid response in metastatic melanoma
Major finding: Tumor reductions of at least 80% were seen at 12 weeks in 11 of 37 (30%) of patients.Data source: A phase-I, dose-ranging study of...
News
PD-L1 blocker shrinks tumors with modest adverse events
Major finding: MPDL3280A, an engineered PD-L1 targeted antibody, shrank tumors by at least 50% in 29 of 140 patients, for an overall response rate...
